GenSciences Raises $124 Million for New Drug Development

GenSciences, a commercial-stage Changchun drug company, has raised over $124 million in its series A and B rounds, the company announced. GenSci is a wholly owned subsidiary of Changchun High-Tech Industry, which was started as a construction company, but narrowed its focus to life science. Its portfolio includes genetically engineered pharmaceuticals, biological vaccines and modern traditional Chinese medicine. In November 2020, GenSci in-licensed China rights to ready-to-use subcutaneous depot formulations for a prostate cancer therapy from Taiwan 's Foresee Pharma. More details.... Stock Symbol: (SHZ: 000661) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.